Figure 9 - available via license: Creative Commons Attribution 3.0 Unported
Content may be subject to copyright.
Source publication
Platelet rich fibrin (PRF) is an autologous biological product which becomes popular day by day and available in a wide variety of fields in medicine. Platelet concentrates which are introduced at the early 90s have evolved over the years. The use such autologous materials have become trendy in recent years to encounter demanding expectations of pa...
Context in source publication
Context 1
... management of patient with compromised healing in bone is controversial. Despite the conventional treatment modalities, curettage of necrotic bone, antibiotic usage, chlorhexidine glukonate; with more complex treatment modalities hyperbaric oxygen therapy, ozone and low dose laser; PRF utilization alone or with these treatment modalities takes place in recent years (Figure 9) [27]. ...
Citations
... Recent studies, such as that by Makki et al. (2021) (Makki et al. 2021), corroborate these findings, highlighting the effectiveness of A-PRF in promoting faster and less painful recovery. In addition, research by Saglanmak, Cinar and Gultekin (2020) (Saglanmak et al. 2020) suggests that the application of A-PRF can significantly improve tissue regeneration and healing. These data indicate that while I-PRF offers benefits in the management of edema, A-PRF may be a more comprehensive and effective option for the overall management of postoperative symptoms in dental surgery. ...
Injectable platelet-rich fibrin (I-PRF) is primarily found in liquid form and plays a role in accelerating vascularization and aiding wound healing. To carry out a critical analysis of the therapeutic potential of injectable platelet-rich fibrin (I-PRF) in the postoperative management of these surgeries. The systematic review protocol for this study included start and end dates, research question, databases, PICO structure, search strategy, inclusion/exclusion criteria, types of studies, measures of effect, screening methods, data extraction/analysis and risk of bias assessment tools. Registered with PROSPERO (CRD42024537367), it guaranteed transparency and quality. Searches were carried out on the PubMed, Scopus, Embase, Wiley Online Library and Web of Science databases. Results: The systematic search in the databases identified 532 studies. After removing duplicates with Rayyan© software, 480 documents remained, of which 15 met the inclusion criteria. After evaluation following the review protocol, 5 studies were considered highly relevant and included in the systematic review. The results indicated not only uncomplicated healing and adequate osseointegration, but also a significant improvement in comfort parameters and post-operative recovery. It was observed that the application of I-PRF accelerated the healing process, reduced pain and edema, and improved soft and hard tissue regeneration.
... PRF serves as a supportive template for tissue regeneration by guiding clot formation through sustaining growth factors and stem cells as a naturally forming fibrin scaffold. There are many applications of PRF in cosmetic medicine and surgery [38][39]. Further research is expected to uncover more benefits to be obtained from PRF's regenerative properties, bioavailability, and autologous nature. ...
Diabetes is a leading chronic illness in the modern world and 19-34% develop chronic diabetic foot ulcers (DFUs) in their lifetime, often necessitating amputation. The reduction in tissue growth factors and resulting imbalance between proteolytic enzymes and their inhibitors, along with systemic factors impairing healing appear particularly important in chronic wounds. Growth factors applied topically have thus been suggested to be a non-invasive, safe, and cost-effective adjunct to improve wound healing and prevent complications.
Comprehensive database searches of MEDLINE via PubMed, EMBASE, Cochrane, and ClinicalTrials.gov were performed to identify clinical evidence and ongoing trials. The risk of bias analysis included randomized controlled trials (RCTs) was performed using the Cochrane Risk of Bias 2.0 tool. We included randomized controlled trials that compared the use of a topical biologic growth factor-containing regimen to any other regimen. Primary outcomes of interest were time to wound closure, healing rate, and time. Secondary outcomes included the incidence of adverse events such as infection.
A total of 41 trials from 1992-2020 were included in this review, with a total recorded 3,112 patients. Platelet-derived growth factors (PDGF) in the form of becaplermin gel are likely to reduce the time of closure, increase the incidence of wound closure, and complete wound healing. Human umbilical cord-related treatments, dehydrated human amnion and chorion allograft (dHACA), and hypothermically stored amniotic membrane (HSAM), consistently increased the rates and incidence of complete ulcer healing while reducing ulcer size and time to complete ulcer healing. Fibroblast growth factor-1 (FGF1) showed only a slight benefit in multiple studies regarding increasing complete ulcer healing rates and incidence while reducing ulcer size and time to complete ulcer healing, with a few studies showing no statistical difference from placebo. Platelet-rich fibrin (PRF) is consistent in reducing the time to complete ulcer healing and increasing wound healing rate but may not reduce ulcer size or increase the incidence of complete ulcer healing.
Targeting the wound healing pathway via the extrinsic administration of growth factors is a promising option to augment wound healing in diabetic patients. Growth factors have also shown promise in specific subgroups of patients who are at risk of significantly impaired wound healing such as those with a history of secondary infection and vasculopathy. As diabetes impairs multiple stages of wound healing, combining growth factors in diabetic wound care may prove to be an area of interest. Evidence from this systematic literature review suggests that topical adjuncts probably reduce time to wound closure, reduce healing time, and increase the healing rate in patients with chronic DFUs.
... Bu faktörler, inflamasyon süreci için gereklidir ve iyileşmeyi artırmada olumlu etkileri vardır. 5 Otolog bir ürün olduğu için alerjik reaksiyonlara neden olmaz, hızlı ve kolay hazırlanabilir, hastalık bulaşma riski ve donör saha morbiditesi riski yoktur. Başlıca avantajları, inflamasyonu kontrol etmek ve lökosit ve sitokin salgısı ile enfeksiyonu baskılamaktır. ...
... i-PRF is a platelet concentrate in liquid form that can be polymerized with bone graft xenograft and is known as sticky bone (sticky PRF), an emerging trend that has gained applications in periodontology and implantology. [12][13][14] There is a paucity of data on the possibility of incorporating L-PRF in PAOO toward achieving a better surgical outcome and healing and the graft materials used in PAOO have not been compared. [15][16][17] The aim of this pilot study was to compare the effectiveness of PRF vs demineralized bone xenograft (DMBM) in affecting the rate of space closure and early wound healing in the PAOO procedure. ...
Objectives
To compare the rate of extraction space closure between periodontally accelerated osteogenic orthodontics (PAOO) using platelet-rich fibrin (PRF) (Group 1) and PAOO using demineralized bone xenograft (DMBM) (Group 2) and to compare the level of wound healing between the PRF group vs the DMBM group after PAOO.
Materials and Methods
A two-arm prospective single blind pilot study with a split-mouth design was used in which 14 patients requiring premolar extraction were divided into two groups: PRF and DMBM. En-masse space closure was carried out with using mini implants after the PAOO procedure. The amount of space closure was measured at five time points with 2-week intervals within 2 months. The gingival healing levels were assessed using early wound healing scores on the first postoperative day.
Results
The rate of extraction space closure was faster in the experimental quadrant at all time points (T1-T4) in the PRF group and at time points (T3, T4) in the DMBM group. Comparison between experimental quadrants showed a significant increase in the rate of space closure in the PRF group T1 to T3 (P < .05). The PRF group showed higher total early healing scores than the DMBM group.
Conclusions
PRF, when used in the PAOO procedure, produces a faster rate of space closure with better early wound healing than DMBM.
Gömülü alt 20 yaş dişlerinin çekimi ağız, diş ve çene cerrahisinde en sık uygulanan cerrahi işlemlerdendir. Bu cerrahi işlemde genellikle; bir dizi fizyolojik, hücresel yanıtı uyaran bir travma oluşur. Bu durum trismus, ödem ve ağrı gibi postoperatif semptomların ortaya çıkışını sağlar. Bu komplikasyonların azaltılmasına yönelik çeşitli yöntemler uygulanmaktadır. TZF-KBF gibi otolog kan ürünleri bu etkilerin azaltılması amacı ile kullanılan yöntemlerdendir. Çalışmamızda TZF’ye göre daha zengin büyüme faktörleri içeren ve daha yoğun fibrin yapısı olan KBF’nin, postoperatif ağrı, ödem ve yara iyileşmesi üzerindeki etkilerinin, TZF’ye göre farkını incelemek amaçlanmıştır. Çalışmamızda 2021 Aralık– 2022 Aralık tarihleri arası XXX, Anabilim Dalı’nda kayıt altına alınan bilateral gömülü alt yirmi yaş dişi cerrahisi yapılmış, 18 yaş üstü 30 hastanın bilgileri, formları ve röntgenleri kullanılmıştır. Çalışmamızda ağrının değerlendirilmesi, postoperatif 2. ve 7.günlerde VAS ile ödemin değerlendirilmesi postoperatif 2. ve 7. Günlerde; hastaların, tragus-ağız köşesi, tragus-pogonion ve lateral göz köşesi-angulus mandibula arası mesafelerin ölçülmesiyle, yara iyileşmesinin değerlendirilmesi postoperatif 7. günde LTH yara iyileşme indeksiyle yapılmıştır. Sonuçlar istatistiksel olarak değerlendirilmiştir. Çalışmamızda KBF ve TZF uygulamasının yara iyileşmesine, postoperatif ödeme ve postoperatif ağrıya olan etkileri incelendiğinde; istatistiksel olarak KBF’nin, TZF’den yara iyileşmesinde daha iyi sonuçlar verdiği ve ağrıyı daha fazla azalttığı saptanmıştır. Postoperatif ödem üzerinde ise KBF’nin TZF’ den istatistiksel olarak farklı olmadığı saptanmıştır.
